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Background: The standard MR Dixon-based attenuation correction (AC) method in Positron Emission Tomography / Magnetic 
Resonance (PET/MR) imaging segments only the air, lung, fat and soft-tissues (4-class), thus neglecting the highly attenuating 
bone tissues and affecting quantification in bones and adjacent vessels. We sought to address this limitation by utilizing the 
distinctively high bone uptake rate constant Ki expected from 18F-Sodium Fluoride (18F-NaF) to segment bones from PET data and 
support 5-class hybrid PET/MR-driven AC for 18F-NaF and 18F-Fluorodeoxyglucose (18F-FDG) PET/MR cardiovascular imaging.  
Methods: We introduce 5-class Ki/MR-AC for (i) 18F-NaF studies where the bones are segmented from Patlak Ki images and 
added as the 5th tissue class to the MR-Dixon 4-class AC map. Furthermore, we propose two alternative dual-tracer protocols to 
permit 5-class Ki/MR-AC for (ii) 18F-FDG-only data, with a streamlined simultaneous administration of 18F-FDG and 18F-NaF at 
4:1 ratio (R4:1), or (iii) for 18F-FDG-only or both 18F-FDG and 18F-NaF dual-tracer data, by administering 18F-NaF 90 min after 
an equal 18F-FDG dosage (R1:1). The Ki-driven bone segmentation was validated against Computed Tomography (CT)-based 
segmentation in rabbits, followed by PET/MR validation on 108 vertebral bone and carotid wall regions in 16 human volunteers 
with and without prior indication of carotid atherosclerosis disease (CAD).  
Results: In rabbits, we observed similar (<1.2% mean difference) vertebral bone 18F-NaF SUVmean scores when applying 5-class 
AC with Ki-segmented bone (5-class Ki/CT-AC) versus CT-segmented bone (5-class CT-AC) tissue. Considering the PET data 
corrected with continuous CT-AC maps as gold-standard, the percentage SUVmean bias was reduced by 17.6% (18F-NaF) and 15.4% 
(R4:1) with 5-class Ki/CT-AC versus 4-class CT-AC. In humans without prior CAD indication, we reported 17.7% and 20% higher 
18F-NaF target-to-background ratio (TBR) at carotid bifurcations wall and vertebral bones, respectively, with 5- versus 4-class AC. 
In the R4:1 human cohort, the mean 18F-FDG TBR increased by 12.2% at carotid bifurcations wall and 19.9% at vertebral bones. 
For the R1:1 cohort of human without CAD indication, mean TBR increased by 15.3% (18F-FDG) and 15.5% (18F-NaF) at carotid 
bifurcations and 21.6% (18F-FDG) and 22.5% (18F-NaF) at vertebral bones. Similar TBR enhancements were observed whe 
applying the proposed AC method to human subjects with prior CAD indication.. 
Conclusions: Ki-driven bone segmentation and 5-class hybrid PET/MR-driven AC is feasible and can significantly enhance 18F-
NaF and 18F-FDG contrast and quantification in bone tissues and carotid walls.    
 





Positron Emission Tomography (PET) has enabled the in-vivo quantitative imaging of numerous radio-pharmaceutical 
tracers by time-coincidentally detecting two emitted gamma photons travelling through tissue in opposite directions 
(1, 2). However, the photons may be absorbed or scattered before reaching the detectors resulting in PET signal 
attenuation, which is quantified by the attenuation coefficients (ACFs) (1, 3). Attenuation correction (AC) can be 
performed by estimating the tissue ACFs distribution, known as AC maps. Hybrid PET and Computed Tomography 
(CT) systems allow the estimation of highly-accurate CT-based AC (CT-AC) maps for superior PET quantification 
(4, 5). Nevertheless, PET/CT detectability may be limited for some lesions due to CT’s low soft-tissue contrast (6).  
Simultaneous PET and Magnetic Resonance (MR) systems have recently enabled the co-registration of PET images 
of highly specific molecular activity with multi-parametric MR images of superior soft-tissue resolution (7-9). Yet 
MR-based AC (MR-AC) may not be as accurate as CT-AC, due to MR’s inherent limitations in ACFs quantification, 
especially for highly attenuating tissues, such as cortical bones (10-12). Currently, PET/MR scanners employ MR-
Dixon sequences to segment all tissues into four classes, namely air, lungs, fat and soft-tissues, each assigned a discrete 
ACF value (13).  Thus, the bones are notably neglected in 4-class MR-AC leading to PET quantification errors in 
adjacent-to-bone regions (12). 
Recently, atlas-based segmentation methods enabled bone ACF estimation by registering bone atlases from past 
human studies (14, 15). However, this approach has limitations due to potential misregistrations and quantitative errors 
between the atlas and the current subject’s actual bone ACF distribution (16). Alternatively, bone AC maps can be 
estimated from special MR sequences, such as ultra-short echo time (17), which require additional scan time and may 
not be uniformly accurate across different bone tissue types (18). To address these limitations, bone segmentation can 
instead be guided by 18F-Sodium Fluoride (18F-NaF) net uptake rate constant (Ki), which has been associated with 
distinctively higher values at bones, compared to the standardized uptake value (SUV) (19, 20).  
In this study, we introduce a novel hybrid PET- and MR-driven 5-class AC method to segment cortical bone tissues 
from the generalized Patlak (gPatlak) Ki images (21, 22), as estimated from dynamic 18F-NaF or dual-tracer 18F-
FDG:18F-NaF PET data (23), while employing the 4-class MR Dixon-based segmentation for the remaining 4 tissue 
classes (13). Unlike standard Patlak, which assumes irreversible uptake, the gPatlak method accounts for the likelihood 
of mildly reversible radiotracer uptake in tissue to more accurately estimate Ki in bones (21, 22). We hypothesize that 




lesions quantification at bones or adjacent carotid arteries in PET/MR using 18F-NaF and 18F-FDG, which are two 
established radiotracers in cardiovascular imaging (24-29). 
 
Materials and Methods 
Initially, the proposed 5-tissue class hybrid PET/MR-AC framework was (i) streamlined for dynamic 18F-NaF 
PET/MR protocols. Later, to extend its application to the well-established 18F-FDG tracer, we also introduced two 
dual-tracer dynamic 18F-FDG:18F-NaF PET/MR protocols involving either (ii) the nearly simultaneous injection of 
the two compounds at an optimal 4:1 dosage ratio (R4:1), which aims at the AC of the 18F-FDG distribution only, or 
(iii) the delayed 18F-NaF administration 90 min after an equal 18F-FDG dosage (R1:1), to support the independent AC 
of either compound (Fig. 1). (30). The total administered dosage in all three protocols is the same following the clinical 
guidelines (31).  
 
Hybrid PET/MR-AC for 18F-NaF PET/MR studies 
The first protocol involved administering 18F-NaF followed by a 90 min list-mode PET acquisition to track 18F-NaF 
concentration in blood (input function, IF) and tissues (Fig. 1a, 1st row). The list-mode data was then histogrammed 
into 12×10 sec, 12×20 sec, 6×60 sec, 4×120 sec and 14×300 sec frames followed by Ordered Subsets – Expectation 
Maximization iterative reconstruction (4 iterations, 21 subsets) with a 4-class MR-AC map (13). The time-activity 
curves at every voxel 系岫建岻, and the IF 系椎岫建岻 were then fitted to the gPatlak model (Eq. 1) using a Basis Function 
Method to obtain parametric images of Ki, total blood distribution volume 撃 and reverse uptake rate constant 倦鎮墜鎚鎚 
(22). Subsequently, the bones were segmented from the Ki image by setting a bottom threshold (Fig. 1d left).  
察岫嗣岻 噺 皐餐 完 察使岫滋岻蚕貸暫残伺史史岫嗣貸滋岻纂滋嗣宋 髪 惨察使岫嗣岻        (1) 
In all protocols, a fixed Ki bottom threshold of 0.001 mL/g/min was used to segment the human bone tissues. 
Moreover, a bottom threshold of SUV=2 was employed on the static 18F-NaF images, 60-90 min post injection (p.i.), 
as an alternative segmentation criterion (20) and the resulting masks were compared against the Ki-segmented bone 
masks. 
Meanwhile, the standard MR-Dixon-based 4-class MR-AC map was built by assigning a discrete ACF value (cm-




added as the 5th tissue class (bone ACF=0.12 cm-1) (32) to build the 5-class Ki/MR-AC map which was used by a new 
image reconstruction to produce the final PET image. 
 
Hybrid PET/MR-AC for 18F-FDG PET with nearly simultaneous 18F-FDG:18F-NaF administration 
In order to apply the 5-class Ki/MR-AC method to 18F-FDG studies, we introduced a second PET/MR scan protocol 
involving the nearly simultaneous administration, within a 3-5 minute interval, of the 18F-FDG and 18F-NaF 
compounds, followed by a 90min list-mode PET/MR acquisition (Fig. 1b) (23). Although simultaneous injection can 
be easier adopted in clinic, it may hamper the discrimination between the two tracers in regions of common uptake, 
due to potentially similar kinetics. This protocol was therefore designed for PET studies aiming at 18F-FDG uptake 
evaluations with the 18F-NaF dosage being utilized only for Ki-driven bone segmentation. The 18F-FDG:18F-NaF 
dosage ratio was optimized with a series of rabbit studies to determine the minimum 18F-NaF dosage necessary for 
robust Ki-driven bone segmentation without significantly contaminating the 18F-FDG uptake in the targeted regions 
of interest (ROIs). 
The bone tissues were segmented by thresholding the gPatlak Ki image, as estimated from the dynamic 18F-FDG:18F-
NaF images (Fig. 1d, left). The same dynamic frame sequence and Dixon-based 4-class MR-AC of the first protocol 
were employed. However, only for this protocol and for scan fields-of-view (FOVs) that include the brain cortex, any 
voxels with SUVs, at 60-90min p.i., higher than an empirical upper threshold of SUV=6 were excluded from the Ki-
segmented bone mask, as they were exclusively associated with the human brain cortex in all human exams of this 
study (Fig. 1d, right). 
 
Hybrid PET/MR-AC of 18F-FDG and 18F-NaF PET by delaying the 18F-NaF administration 
The third PET/MR protocol involved administration of an 18F-NaF dosage 90 min after an equal 18F-FDG dosage 
(R1:1) and a 90 min scan commencing 75 min after 18F-FDG injection (Fig. 1c). Thus, the 5-class Ki/MR-AC of net 
18F-FDG data prior to 18F-NaF administration becomes possible. Moreover, the independent 5-class Ki/MR-AC of 
both 18F-FDG and 18F-FDG data for dual-tracer studies can be attained with this protocol. A sequence of 3×5 min 18F-
FDG images from the first 15 min and a population-based 18F-FDG IF model (33), to infer the missing IF data of the 




The fitted IF and 18F-FDG gPatlak parameters were then utilized to predict, according to the gPatlak method, the net 
dynamic 18F-FDG distribution after the 18F-NaF injection (last 75min of scan). 
To construct the carotid 18F-FDG IF model, we extracted a set of six 18F-FDG human carotid image-derived IFs 
(IDIFs) from the respective set of dynamic 18F-FDG PET/MR carotid 90min scans of cohort A subjects with no prior 
indication of carotid atherosclerosis disease (CAD) to minimize contaminating the IDIF measurements with signal 
from atherosclerotic plaques in the carotid walls. The IDIFs were drawn from blood pool ROIs placed in the lumen of 
the common carotid sections and as distant as possible from the carotid walls and the bifurcations to further minimize 
potential spill-in of activity from atherosclerotic plaques developed in arterial walls. Subsequently, the carotid IDIFs 
were normalized to the injected dosage of each exam, fitted to the Feng’s IF parameterized model (34), shifted in time 
to match their IF peak post-injection times and averaged together to form a single carotid IF model curve. 
Subsequently, to estimate the missing early section of the carotid 18F-FDG IF for an R1:1 PET/MR carotid exam, the 
late section of the modeled IF curve (75-90min post injection) was fitted to the carotid 18F-FDG IDIF measurements 
of the R1:1 exam as obtained during the same post 18F-FDG injection time window (fist 15min of R1:1 scan) from 
ROIs drawn on the same common carotid lumen regions as those used for the estimation of the IF model (33). It 
should be noted that the aforementioned process to extrapolate the IDIF of the R1:1 exams to the early post-injection 
time window (0-75min post 18F-FDG injection) is required only for the purpose of estimating a single value, namely 
the time integral of the IDIF from 18F-FDG injection time to the start of the scan 75min later according to the Patlak 
Eq. (1). As a result the gPatlak method to estimate Ki is expected to be sufficiently robust and less sensitive to potential 
inaccuracies in the population IF model and spill-in of arterial wall activity. The estimated 18F-FDG IF and gPatlak 
parameters were then utilized to predict, according to the gPatlak model (Eq. 1), the net dynamic 18F-FDG distribution 
after the 18F-NaF injection (last 75min of scan). 
Meanwhile, the list-mode dual-tracer PET data acquired after the 18F-NaF administration was histogrammed along 
the same frames sequence relative to 18F-NaF injection time, as in previous protocols, and reconstructed with a 4-class 
MR-AC map. The previously extrapolated dynamic 18F-FDG images were the subtracted from the corresponding dual-
tracer images to estimate the dynamic net 18F-NaF images for the last 75 min. The steps used for building the 18F-FDG 
IF model were also followed to construct a carotid 18F-NaF IF model from the respective set of six dynamic 18F-NaF 
PET/MR carotid 90min scans of cohort A subjects. Subsequently, the 18F-NaF IF model curve was fitted to IDIF 




18F-NaF IF and the 18F-NaF dynamic images were used as an input to the gPatlak method to estimate the 18F-NaF Ki 
image, segment the bone tissues and build the 5-class Ki/MR-AC map. We used a population-based 18F-NaF IF model 
from IDIF data derived from cohort A subjects without prior CAD indication as the possibility of plaques development 
in the arterial walls and, thus, of spill-in of arterial wall activity is lower for these subjects. 
Finally, the reconstructions of the 18F-FDG and the dual-tracer data, before and after the 18F-NaF administration 
respectively, were repeated with the 5-class Ki/MR-AC map. We then extrapolated the new 18F-FDG images for the 
last 75 min of scan and subtracted them from the respective dual-tracer images to estimate the final 18F-NaF images. 
 
Pre-clinical validation of Ki- against CT-driven bone segmentation 
The proposed Ki-driven bone segmentation method was validated on two healthy rabbits (4.4 and 5.6kg), with a 
series of 90 min list-mode PET/CT exams over two weeks in a Siemens BiographTM mCT (Knoxville, TN, USA) 
scanner (35) using five administration schemes: 18F-FDG, 18F-NaF or 18F-FDG:18F-NaF dosages at 1:1, 4:1 or 9:1 
simultaneously-injected ratios (total dosage: 139 +/- 8 MBq, 3.76 +/- 0.19 mCi). All procedures were in accordance 
with the ethical standards of the Institutional Animal Care and Use Committee (IACUC) of the Icahn School of 
Medicine at Mount Sinai. 
In order to emulate the effect of discretized multi-tissue class MR-AC maps, we synthesized 4- and 5-class AC 
maps, for each of the 18F-NaF and 4:1 18F-FDG:18F-NaF PET/CT scans, by segmenting the continuous CT-AC map 
and assigning a fixed ACF value to each class (32). The CT-segmented bone mask consisted of all CT-AC voxels with 
original ACFs higher than 0.105cm-1. Furthermore, we generated a 5-class PET/MR-AC map by applying Ki-driven 
bone segmentation and assigning the remaining non-bone voxels to the conventional 4 tissue classes according to their 
CT-AC values. The same ACF value (0.12cm-1) was assigned to both CT- and Ki-segmented bone masks. Next, we 
evaluated the percentage (%) difference maps between the PET images corrected with each of the different discretized 
AC maps and a PET image corrected with the gold-standard continuous CT-AC maps. Thus, we compared the effect 
on PET images of Ki- against CT-driven bone segmentation for the same set of discretized ACFs. The same rabbits 
underwent a similar series of PET/MR exams (142 +/- 9 MBq, 3.84 +/- 0.22 mCi) using a Siemens BiographTM mMR 
(Erlangen, Germany) scanner (36) to determine the minimum 18F-NaF dosage ratio for which Ki-driven bone 






Clinical performance evaluation in carotid PET/MR imaging 
The clinical performance of the 5-class Ki/MR-AC methods was evaluated on 11 human volunteers (45 +/- 14 y.o., 
86 +/- 14kg, 5 males, 6 females) with no prior indication of atherosclerosis randomly assigned into cohorts A and B 
of 6 and 5 members, respectively. Cohort A subjects underwent a series of three carotid PET/MR scans within 21 +/- 
4 days involving (i) 18F-FDG (171 +/- 10 MBq, 4.62 +/-0.27 mCi), (ii) 18F-NaF (173 +/- 11 MBq, 4.68 +/-0.30 mCi) 
and (iii) simultaneously injected R4:1 18F-FDG:18F-NaF (344 +/- 24 MBq, 9.30 +/- 0.65 mCi) dosages. Cohort B 
subjects underwent an 18F-FDG:18F-NaF R1:1 scan with 18F-NaF administration (181 +/ 11 MBq, 4.90 +/- 0.30 mCi) 
90 min after 18F-FDG (179 +/- 10 MBq, 4.84 +/- 0.27 mCi) followed by a 18F-NaF PET/MR scan (178 +/- 17 MBq, 
4.81 +/-0.46 mCi)) within 10 +/- 2 days. Subsequently, 5 human subjects (49 +/- 13 y.o., 89 +/- 15kg, 2 males, 3 
females) with a prior indication of CAD were assigned to cohort C and underwent the same type of PET/MR scans as 
the subjects of cohort B: an 18F-FDG:18F-NaF R1:1 PET/MR scan with 18F-NaF (188 +/ 15 MBq, 5.08 +/- 0.41 mCi) 
administered 90 min after 18F-FDG (183 +/- 13 MBq, 4.95 +/- 0.35 mCi) followed by a 18F-NaF PET/MR scan (180 
+/- 17 MBq, 4.86 +/-0.46 mCi) within 10 +/- 2 days. The aim of cohort C was to evaluate the performance of the 5-
class Ki/MR-AC methods on carotid plaque SUV quantification for both tracer compounds. In all cases, we performed 
a standard MR-Dixon, a 3D Time-of-Flight MR angiogram, T1-, T2-weighted and proton density turbo spin echo 
sequences. The study was approved by the institutional review board ethics committee, and informed consent was 
signed by all enrolled subjects. 
A total of 108 carotid wall and adjacent vertebral bone regions were assessed. Specifically, in the 18F-NaF studies 
of cohort A, the target-to-background (TBR) scores were evaluated for 12 carotid wall regions (at the right and left 
bifurcation of each subject) and 12 adjacent vertebral bone lesions (2 per subject) between 18F-NaF images corrected 
with 4- versus 5-class Ki/MR-AC. The analysis was then repeated for the R4:1 18F-FDG:18F-NaF images of the same 
subjects cohort at the same 24 regions. In cohorts B and C, the TBR analysis was conducted in the 18F-FDG and 18F-
NaF co-registered images for three regions per subject: the carotid wall regions at the right and left bifurcation and 
one adjacent vertebral bone tissue (15 regions per cohort per tracer). 
The carotid TBR scores were evaluated by averaging across the maximum SUV per transaxial slice of a target ROI 
at the left or right bifurcation and then dividing by the mean SUV of a background ROI at the respective common 




large cervical vertebra ROI over the mean SUV of a background ROI at an adjacent soft-tissue region. All ROIs were 
manually drawn as ellipsoids from the coregistered MR angiograms at matched locations. The influence of partial-
volume spill-over effects from the hot target to the surrounding warm background regions were mitigated by 
evaluating the maximum, instead of the mean, SUVs per slice in the target ROIs, over regions of relatively large 
surface (bifurcations, common carotids and larger vertebrae). Finally, two-tailed paired t-tests were conducted for 
each TBR comparison. A value of p<0.05 was considered significant. 
 
Results 
Evaluation of different ratios of simultaneously-injected 18F-FDG:18F-NaF dosages in PET/CT and PET/MR studies 
of the same rabbit showed that all ratios ≤ 4:1 triggered distinctively higher vertebral bone Ki scores, relative to 18F-
FDG, thus suggesting an optimal ratio of 4:1 for bone segmentation (Fig. 2).  
Moreover, the PET/CT results in Fig. 3 from the same rabbit illustrated the satisfactory alignment between 
continuous CT-AC (gold-standard) and Ki-segmented AC bone maps from 18F-NaF or simultaneously-injected 18F-
FDG:18F-NaF ≤ 4:1 ratios. For the same data, we calculated PET bias maps (Fig. 4), displaying the % SUV difference, 
with respect to PET images corrected with continuous CT-AC maps (gold standard), of PET images corrected with 4- 
and 5-class segmented CT-AC maps and with proposed 5-class Ki/CT-AC maps (gPatlak Ki-segmented bone defined 
as fifth tissue class). Our results showed that the mean SUV % bias was reduced by 17.6 +/- 6.3% (18F-NaF) and 15.4 
+/- 5.7% (18F-FDG:18F-NaF R4:1) at the arrow-designated vertebral bone regions with 5-class Ki/CT-AC versus 4-
class CT-AC. At the same regions, the 5-class Ki/CT-AC yielded similar SUVmean uptake values to those of 5-class 
CT-AC (difference of -0.4 +/- 2.5% for 18F-NaF and 1.2% +/- 1.5% for 18F-FDG:18F-NaF R4:1), thus suggesting a 
satisfactory accuracy for Ki-driven bone segmentation. 
Fig. 5 illustrates the superior accuracy of Ki- vs. SUV-driven bone segmentation in 18F-NaF PET/MR studies, due 
to the higher bone-to-soft-tissue Ki contrast. Moreover, similar results were observed with the R4:1 18F-FDG:18F-NaF 
simultaneous injection protocol, thereby indicating the feasibility of utilizing the proposed Ki/MR-AC method for 18F-
FDG PET/MR studies as well.  
In the human carotid 18F-NaF PET/MR images presented in Fig. 6, we observed an 18F-NaF TBR average increase 
of 17.7% (p=0.009) in the carotid bifurcations wall and 20% (p=0.004) in the vertebral bones with 5-class Ki/MR-AC 




when SUV images were used instead as the bone segmentation criterion (SUV/MR-AC). Regarding the 18F-FDG:18F-
NaF R4:1 simultaneous administration protocol, we observed in Fig. 7 a TBR average increase of 12.2% (p=0.032) at 
the left and right carotid bifurcations and 19.9% (p=0.006) at the adjacent vertebral bone regions with 5-class Ki/MR-
AC vs. 4-class MR-AC.  
In Fig. 8, we demonstrated the feasibility of applying 5-class Ki/MR-AC to 18F-FDG and 18F-NaF carotid data from 
the same scan as performed on human subjects without prior indication for CAD by using the R1:1 18F-FDG:18F-NaF 
PET/MR protocol with delayed 18F-NaF administration 90min post 18F-FDG administration. The bifurcations’ mild 
contrast accords well with literature for 18F-FDG (TBR<1.9) and 18F-NaF (TBR<1.6) in healthy subjects (24, 26). The 
mean TBR increase in the left and right carotid bifurcations was 15.3% (p=0.009) and 15.5% (p=0.002) for 18F-FDG 
and 18F-NaF images, respectively. The respective TBR increase in three adjacent vertebral bone regions was 21.6% 
(p=0.004) for 18F-FDG and 22.5% (p=0.002) for 18F-NaF. 
Finally, in Fig. 9, we repeated the same clinical evaluation of the performance of 5-class Ki/MR-AC method using 
the same R1:1 18F-FDG:18F-NaF PET/MR protocol but on human carotid data acquired from human subjects with 
prior indication for CAD (cohort C). In this case, the average contrast at the carotid bifurcations, regardless of the 
applied AC method, was higher than 2 in accordance with TBR criteria established in literature (24, 26). Both the 18F-
FDG and 18F-NaF TBR was increased at the carotid bifurcations and vertebral bones with the 5-class Ki/MR-AC 
method against 4-class MR-AC. No significant differences were observed in the respective TBR enhancements 
between subject with and without prior CAD indication.     
 
Discussion 
PET bone quantification accuracy attained with 5-class AC maps consisting of Ki-segmented bones and CT-
segmented air, lungs and soft tissue classes (5-class Ki/CT-AC) was similar to that attained with CT-segmented air, 
lungs, soft-tissue and bones (5-class CT/AC) in a series of PET/CT studies of the same rabbit. Moreover, 5-class 
Ki/CT-AC achieved significantly smaller PET bias in rabbit bone tissues compared to the 4-class CT-AC where bone 
was segmented as soft-tissue.  Furthermore, in all human carotid PET/MR studies, we observed significant TBR 
increase in both 18F-NaF and 18F-FDG lesions at vertebral bones and at the adjacent carotid bifurcations for the 5-class 
Ki/MR-AC versus 4-class MR-AC. This is attributed to the larger percentage recovery of the attenuated PET signal in 




soft-tissue and common carotid sections, respectively) ROIs, due to the closer proximity of the target lesions to the 
highly attenuating cortical bone tissues. Past PET/MR studies reported significant PET quantification errors due to 
misregistration of bone as soft-tissue only for regions in close proximity to the misregistered bone tissue (37). It should 
be noted that PET partial volume effects (PVE) in a target region are determined by the size of the targeted region 
with respect to the spatial resolution of the PET scanner. Thus, the same degree of PVE is expected in the target 
regions before and after the inclusion of the Ki-segmented bone mask in the AC maps. Therefore, the observed TBR 
increase in the bones and carotid bifurcation walls is not expected to be affected by PVE.    
Furthermore, a comparable Ki-driven bone segmentation performance was observed between the rabbit and human 
studies for the same Ki threshold criteria and 18F-FDG: 18F-NaF dosage ratio, which allowed the optimization of the 
clinical Ki/MR-AC protocols based on our preclinical findings. The high accuracy in Ki-driven bone segmentation in 
the rabbits was achieved thanks to the sufficient bone-to-soft-tissue contrast-to-noise ratio (CNR) attained in the rabbit 
studies, which remained high despite partial contrast losses expected by PVE due to imaging of small bone tissues of 
rabbits with a human PET/MR scanner of low spatial resolution. The enhanced bone-to-soft-tissue CNR is attributed 
to the high dosage / weight ratios utilized in the rabbit studies to reduce the noise levels and thus enhance the bone-
to-soft-tissue CNR. 
Although the 18F-NaF SUV has previously been used for bone segmentation, its dependence on the acquisition 
timing window and the IF may limit its robustness as a segmentation criterion (20). Furthermore, our results indicated 
significantly reduced bone-to-soft-tissue TBR for 18F-NaF SUV versus 18F-NaF Ki (-68 +/- 11%, p=0.009) and 18F-
FDG:18F-NaF R4:1 Ki (-47 +/- 16%, p=0.037) images, therefore, hampering segmentation accuracy (Fig. 5) and PET 
quantification (Fig. 6). Alternatively, static 18F-NaF could have been used to derive Ki, but only if the IF and V 
parameters were known a-priori, which is not possible for prospective studies (38). 
The gPatlak Ki imaging method was selected to account for the mildly positive tracer uptake reversibility (倦鎮墜鎚鎚 半ど, Eq. 1), as suggested by the progressively reduced bone uptake rate constant Ki measured from later time windows 
(Fig. 2). This method had previously demonstrated enhanced 18F-FDG Ki accuracy and reproducibility, compared to 
standard Patlak (22), and was chosen to ensure a more accurate Ki-driven bone segmentation.  
Our first protocol is streamlined for clinically adoptable bone segmentation but is limited to 18F-NaF-only studies. 
To support Ki/MR-driven AC for the widely established 18F-FDG tracer, we proposed simultaneously administering 




contrast for bone segmentation and satisfactory 18F-FDG quantification. However dosage ratio optimization is required 
to ensure the reliable Ki-driven bone segmentation across multiple human body regions, thus raising the complexity, 
while 18F-FDG bias may be introduced, if the 18F-NaF contribution to the total uptake is non-negligible at the target 
regions. On the other hand, regions that are expected to exhibit high 18F-FDG SUV and Ki scores due to considerable 
metabolic of inflammatory activity, such as the brain cortex or the liver (Fig 3) may be misclassified as bones with 
Ki-driven bone segmentation thereby affecting 18F-FDG quantification through erroneous attenuation correction. This 
limitation may in some cases be addressed with a complementary SUV-based bone segmentation criterion, as it was 
the case with our proposed R4:1 protocol for head-and-neck scans to avoid the brain cortex from being segmented as 
bone, due to the high Ki values triggered in that region after the simultaneous administration of 18F-FDG and 18F-NaF 
compounds. However, other regions can be associated with different 18F-FDG and 18F-NaF kinetic properties and, 
thus, the suggested SUV criterion may be different or unnecessary. Despite that SUV>6 scores were only associated 
with the brain cortex tissue in all our PET/MR studies scanned with the R4:1 protocol, the possibility for a bone region 
exhibiting SUV>6 scores and, thus, not being segmented as bone cannot be excluded. 
Our third protocol may address these limitations by delaying 18F-NaF administration for 90 min after an equal 18F-
FDG dosage, using the same total dosage with previous protocols, to distinguish between the two compounds and 
apply Ki/MR-AC to each (30). This approach can be clinically useful for PET/MR cardiovascular studies aiming at 
quantification of inflammation (18F-FDG) only (24, 25) or both inflammation and micro-calcification (18F-NaF) (26-
28) in carotid walls with a single PET/MR exam (30). This method requires relatively longer total PET scan times and 
two separate injections which, nevertheless, can be accommodated nowadays by simultaneous PET/MR scans and 
automated injection mechanisms. Moreover, the image-based subtraction employed for 18F-NaF estimation may lead 
to erroneous estimates at high noise levels. Nevertheless, despite the reduction of 18F-FDG and 18F-NaF dosages to 
half of the standard dosage, relatively low PET noise levels would be expected for both radiotracers, thanks to the 
small attenuating tissue volume surrounding the carotids, the long PET acquisition times afforded in PET/MR during 
the similarly long parallel MR sequences and the enhanced sensitivity of the Biograph mMR large axial field-of-view 
(36). Although Ki-driven bone segmentation relies on gPatlak analysis of PET and IF data initially corrected with sub-
optimal 4-class MR-AC, no significant differences were observed in the accuracy of the Ki-driven segmentation of 
rabbit bone tissues using either 4-class or 5-class CT-AC maps. Furthermore, any effects on Ki estimation accuracy 




sufficient to account for that bias in all rabbit studies. This is attributed to the sufficient bone-to-soft-tissue contrast 
attained with both AC methods allowing for the satisfactory alignment between Ki- and CT-derived bone masks in 
rabbit PET/CT studies even with the sub-optimal 4-class AC method. The use of a single Ki bone segmentation 
threshold was sufficient to attain similar TBR enhancements with low variance across all human subject studies 
thereby suggesting that Ki-driven bone segmentation from 4-clas MR-AC maps can be reliable in human PET/MR 
scans as well. Finally, it is important to note that atherosclerotic plaques may exhibit calcification resulting in increased 
18F-NaF uptake (30). Nevertheless, none of the Ki voxel values in the carotid bifurcation walls exceeded the threshold 
value required to be segmented as bone tissue for any of the enrolled human subjects regardless of prior CAD 
indication or administration protocol. Thus, the Ki-driven bone segmentation and the PET quantification attained with 
the hybrid Ki/MR-AC method were not affected by the presence of calcification in carotid walls. However, this is an 
effect that we plan to monitor in future when applying the proposed AC method to a larger number of subjects and for 
a wider range of non-bone target regions where calcification is expected, including atherosclerotic plaques in the aorta 
and coronary arteries. 
This proof-of-concept study was focusing on cardiovascular studies and, as such, it was limited to 18F-FDG and 
18F-NaF PET uptake evaluations in the carotid bifurcations and neighboring vertebral bone tissue to assess any 
quantification benefits from including Ki-segmented bone tissue in the absence of CT measurements. Based on 
previous studies and our results here, which suggested no significant quantification effects in lesions distant to bones 
when the bone ACFs are neglected (4-class MR-AC), the proposed methods were not evaluated for cardiac PET 
regions (37).  In addition, no significant correlation was found between the CT-derived bone density and the PET-
derived bone Ki values. This can be attributed to the lower resolution of PET vs. CT and the PET partial volume 
effects expected in the small vertebral bone regions preventing the PET signal discrimination across neighboring bone 
tissue regions of different density. In future, we plan to evaluate 5-class PET/MR-AC methods for larger patient 
cohorts, dynamic whole-body PET protocols of larger axial FOVs to investigate any quantification benefits for more 
regions adjacent to bones (39) and for a larger range of bone densities, as well as direct gPatlak Ki reconstruction for 
improved bone segmentation from PET images with lower noise levels (40). 
Our results indicate that 5-class Ki/MR-AC may significantly improve PET quantification and contrast in lesions 
and regions lying at or closely adjacent to bones, including carotid bifurcations. Furthermore, the presented AC 




imaging. Current state-of-the-art clinical PET systems may readily adopt whole-body Ki-driven bone segmentation 
thanks to their support of whole-body Patlak imaging methods (40). Moreover, the bone AC maps are applied to the 
same PET data from which they are estimated to ensure accurate co-registration between the two datasets. Finally, 
Ki/MR-AC methods can be retrospectively applied to previously acquired PET/MR studies, if dynamic PET data are 
available, and do not require atlas-based bone registrations or additional MR resources. 
 
New knowledge gained 
In this study we validated a novel PET-driven bone segmentation method from Patlak Ki imaging. Furthermore, we 
combined the segmented bones with standard 4-class MR-AC maps to enable 5-class AC in cardiovascular PET/MR 
studies and showed significant enhancements in 18F-NaF and/or 18F-FDG contrast and quantification at human 
vertebral bones and carotids. 
 
Conclusion 
We proposed a robust and clinically adoptable method for Patlak Ki-driven segmentation of human cortical bone 
tissues from 18F-NaF or dual-tracer 18F-FDG:18F-NaF PET data without the need for additional bone atlases or MR 
resources. The Ki-segmented bone tissues can then be combined with standard 4-class MR-AC to significantly enhance 
18F-NaF and/or 18F-FDG lesions contrast and quantification at or adjacent to bones in clinical PET/MR studies.  
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FIGURES AND LEGENDS 
 
Fig. 1. Illustrative overview of (a) 18F-NaF-only, (b) simultaneous R4:1 18F-FDG:18F-NaF and (c) R1:1 18F-FDG with 
delayed 18F-NaF administration protocols (left column) with their respective dynamic courses of activity concentration 







Fig.  2. Preclinical study to optimize the simultaneously injected 18F-FDG:18F-NaF dosage ratio for bone segmentation. 
Non-registered PET sagittal images from (a)  PET/CT and (b) PET/MR data, as acquired from the same rabbit subject 
on different days at 60-90 min after injection of the same total dosage of either 18F-FDG, 18F-NaF or combined 18F-
FDG:18F-NaF (simultaneous injection) at ratios of R9:1, R4:1 and R1:1. (c) Respective time–activity curves from the 
PET/MR data in the same vertebral bone region (arrows) across the different scans. Similar results were obtained from 
a wide set of different vertebra regions. The reduced 18F-FDG uptake at later times suggests 18F-FDG uptake 
reversibility in bones, thereby demonstrating the need for generalized versus standard Patlak Ki imaging. The SUV 






Fig.  3. Coronal and sagittal views of continuous CT-AC maps (gray) fused with the Ki-segmented bone masks (red) 
from PET/CT scans of the same rabbit with 18F-NaF (upper left) or 18F-FDG:18F-NaF simultaneously-injected dosages 
at R1:1 (upper right), R4:1 (bottom left) and R9:1 (bottom right) ratios. The arrows indicate areas of satisfactory 
(green) and non-satisfactory (purple) alignment between CT- and Ki-segmented bone. Note that in case of 
simultaneously-injected 18F-FDG:18F-NaF dosages administered at ratios higher than 4:1, large non-bone regions with 
a high 18F-FDG metabolic uptake, such as the liver, are expected to also exhibit a high Ki score and thus be segmented 






Fig.  4. Rabbit PET/CT validation of Ki-driven bone segmentation: (a) Continuous CT-AC maps for 18F-NaF (up) 
and 18F-FDG:18F-NaF R4:1 (bottom) protocols. (b) Percentage (%) SUV difference (bias) maps, with respect to 
continuous CT-AC PET, of PET images corrected with segmented 4-class CT-AC, 4-class CT-AC + CT-segmented 
bone class (5-class CT-AC) and 4-class CT-AC + Ki-segmented bone class (5-class Ki/CT-AC). Average SUV 







Fig.  5. Clinical demonstration of Ki-driven bone segmentation in a human carotid PET/MR study from a cohort A 
subject. (a) PET-driven bone segmentation criterion: (left-to-right) 18F-NaF SUV (60-90 min p.i.), 18F-NaF Ki (0-90 
min p.i.) and simultaneously-injected 18F-FDG:18F-NaF R4:1 Ki (0-90 min p.i.) (b) Hybrid PET/MR-driven 5-class 






Fig.  6. Clinical evaluation of the 5-class Ki/MR-AC method in human carotid 18F-NaF PET/MR studies from cohort 
A subjects. (top 3 rows, left-to-right): Transaxial, coronal and sagittal views for a single subject of MR angiogram 
fused with 18F-NaF SUV images 60-90 min p.i. corrected with (a)-(c) 4-class MR-AC, (d)-(f) 5-class SUV/MR-AC 
and (g)-(i) 5-class Ki/MR-AC maps. (j) Respective PET TBR scores, averaged across all six subjects of cohort A, at 
left and right carotid bifurcations (blue arrows) and adjacent bones (white arrows). The carotid and bone background 
ROIs were drawn at the common left and right carotids (pink arrows) and a soft-tissue region adjacent to the cervical 






Fig.  7. Clinical evaluation of the 5-class Ki/MR-AC method in human carotid 18F-FDG:18F-NaF (R4:1, 
simultaneously-injected) studies from cohort A subjects. (top 2 rows, left-to-right) Transaxial, coronal and sagittal 
views for a single subject of MR angiograms fused with 18F-FDG:18F-NaF PET SUV images 60-90 min p.i. corrected 
with (a)-(c) 4-class MR-AC and (d)-(f) 5-class Ki/MR-AC maps. (g) Respective PET TBR scores, averaged across all 
six subjects of cohort A, at left and right carotid bifurcations (blue arrows) and adjacent bones (white arrows). The 
carotid and bone background ROIs were drawn at the common left and right carotids (pink arrows) and a soft-tissue 






Fig.  8. Clinical evaluation of the 5-class Ki/MR-AC method in human carotid 18F-FDG:18F-NaF (R1:1, delayed 18F-
NaF administration by 90min post 18F-FDG administration) studies from cohort B subjects (without prior indication 
for carotid atherosclerosis). (top 2 rows, left-to-right): Fusion of transaxial MR angiograms with PET images of a 
single subject corrected with the 4-class AC method. The PET maps represent signal of (a) measured 18F-FDG at 75-
90 min post 18F-FDG administration, (b) extrapolated 18F-FDG, (c) measured dual-tracer 18F-FDG:18F-NaF and (d) 
estimated 18F-NaF at 60-75 min post 18F-NaF administration. (e)-(h) Respective PET/MR fused images corrected with 
the 5-class Ki/MR-AC method. (Bottom row) TBRs of (i) 18F-FDG at 75-90min post 18F-FDG administration and (j) 
18F-NaF at 60-75 min post 18F-NaF administration, averaged across all four subjects of cohort B. The right and left 
carotid bifurcation (blue arrows) and an adjacent bone region (red arrows) were considered as target ROIs. The carotid 
and bone background ROIs were drawn at the common left and right carotids and a soft-tissue region adjacent to the 






Fig.  9. Same qualitative and TBR evaluation of the 5-class Ki/MR-AC PET against the 4-class MR-AC PET as in 
Fig. 8 but for human carotid 18F-FDG:18F-NaF (R1:1, delayed 18F-NaF administration by 90min post 18F-FDG 
administration) studies from cohort C subjects (with prior indication for carotid atherosclerosis). 
 
